Article: N-Gene Research Laboratories, Inc. Reports Positive Phase II Results With BGP-15 Insulin Sensitizer.

- Significant Improvement Seen in Insulin Sensitivity -

NEW YORK, June 12 /PRNewswire/ -- N-Gene Research Laboratories, Inc., a privately held biopharmaceutical company developing products to treat insulin resistance, today presented positive Phase II data for BGP-15, a novel insulin sensitizer. The data were presented in a poster presentation at the American Diabetes Association 66th Scientific Sessions conference in Washington, DC, titled "BGP-15, a Novel Insulin Sensitizer." Presenters included Jesse Roth, M.D., Professor of Medicine, Albert Einstein College of Medicine, former Scientific Director of National Institute of Diabetes and Digestive and Kidney ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!